Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NONO
REST API REST API
Homo sapiens
NONO is differentially expressed in 263 experiments: 143 organism parts: bone marrow, thymus, ... (141 more);, 207 disease states: normal, chronic myelogenous leukemia, ... (205 more);, 96 cell types 367 cell lines 28 compound treatments and 75 other conditions.
Synonyms P54NRB, P54, NRB54, NMT55
Orthologs Nono (Mus musculus)   nono (Danio rerio)   Q5ZIZ5_CHICK (Gallus gallus)   Q2KJ42_BOVIN (Bos taurus)   ENSCING00000004050 (Ciona intestinalis)   nonA-l (Drosophila melanogaster)   nonA (Drosophila melanogaster)   nono (Xenopus laevis)   LOC607081 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, DNA binding, protein binding, DNA repair, regulation of transcription, DNA-dependent, nucleic acid binding, nuclear matrix, identical protein binding, nucleus, DNA recombination, nucleotide binding, mRNA processing, RNA binding, paraspeckles
InterPro Term NOPS, RRM_dom
UniProt Accession Q15233, C9J4X2, C9IZL7, C9JJ13, C9JYS8, F5GYZ3
Search EB-eye ENSG00000147140
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, E-MTAB-62, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
A673
2
E-MTAB-62, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
HCC1143
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
GM00719
1
E-TABM-321
361 more value(s).


Cell type

studied in E-GEOD-16058, E-GEOD-22373, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (45 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-3920, E-GEOD-3998
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD4+ T cell
1
2
E-GEOD-16190, E-AFMX-5, E-TABM-145
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
parental foreskin cells
1
E-GEOD-20033
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-12254, E-MTAB-62, E-GEOD-5370, ... (55 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MEXP-1327, E-MTAB-62
Classic-KS, HIV-, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
201 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (18 experiments)

Factor Value U/D Experiments
AMP
1
1
E-MEXP-2285
unknown
1
E-GEOD-7307
heregulin
1
E-GEOD-6462
glutamine
1
E-MEXP-941
resveratrol
1
E-TABM-782
TGF-Beta1
1
1
E-MEXP-2645
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-16058, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-19665

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-1045, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-3720, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-TABM-585, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.415 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM